Humira (adalimumab) — HCPCS J0135 / J0139

Pharmacy benefit vs. medical benefit — routing the claim correctly Verified May 2026

For adalimumab, the benefit-channel decision happens before any J-code or Q-code is selected.

Adalimumab is a subcutaneous self-injectable. Across the entire adalimumab class — Humira reference and every biosimilar — the dominant utilization pattern is patient self-administration at home, dispensed through a specialty pharmacy and adjudicated under the pharmacy benefit. The medical-benefit J-codes and Q-codes only apply to the small minority of doses administered in a physician's office. Get the routing wrong and the claim either rejects (medical claim for a pharmacy-benefit drug) or duplicates (both channels paid for the same fill).

What this means for your coding workflow

• Step 1: Confirm benefit channel. Pharmacy benefit → route to specialty pharmacy, no claim coding.
• Step 2 (if medical): Identify the exact product (reference vs. specific biosimilar) by NDC.
• Step 3 (if medical): Map to the correct HCPCS — J0135 or J0139 for Humira reference; Q5140–Q5145 for the six Q-coded biosimilars; J3490/J3590/C9399 for the four un-Q-coded biosimilars.
• Step 4 (if medical): Add 96372 admin code, NDC in 24A shaded area, ICD-10 matching the indication.

Six Q-coded adalimumab biosimilars — side by side FDA Purple Book verified May 2026

Same molecule, same dose, same indications — different HCPCS, different NDC, different formulation, different payer preferences.

Ten adalimumab products are now FDA-approved: Humira reference plus nine biosimilars. Six biosimilars carry permanent CMS Q-codes (Q5140 through Q5145). The remaining four (Amjevita, Hadlima, Hyrimoz, Yusimry) bill medically under unclassified codes (J3490 / J3590 / C9399) until CMS issues product-specific Q-codes. Four biosimilars are FDA-designated interchangeable, allowing pharmacy-level substitution where state law permits without prescriber intervention.

Biosimilars without dedicated Q-codes (bill unclassified when medical)

Dosing by indication FDA label current

From FDA prescribing information (BLA 125057) — Humira reference; biosimilar dosing identical.

Humira's label covers ten indications across four therapeutic areas. Dosing varies materially by indication — especially loading-dose strategies for IBD and the weekly schedule for hidradenitis suppurativa.

Worked example — adult RA, 40 mg q2wk, in-office administration (rare)

Hidradenitis suppurativa — the only weekly indication

HS dosing is unusual: after the standard 160 mg / 80 mg loading sequence, maintenance is 40 mg weekly, not every other week. This doubles the annualized dose count (52 vs. 26) and is the most common dosing-error pattern at PA submission. Confirm HS-specific dosing is requested when ICD-10 L73.2 is on the claim.

NDC reference — common Humira & biosimilar SKUs FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Adalimumab is non-chemotherapeutic and subcutaneous — use therapeutic SC injection codes, not chemo.

Modifiers CMS verified May 2026 — verify JZ list

JZ — whole-syringe use, default expectation when in office

Effective July 1, 2023, CMS requires JZ on all claims for single-dose container drugs when no drug is discarded — but only for codes on the CMS single-dose container list. Adalimumab's 40 mg dose uses one full prefilled syringe or pen with no discard, so JZ is the expected modifier when J0135 or J0139 appears on that list. Verify against the current CMS single-dose container list at billing time; the list is updated periodically.

JW — rarely applies

The 40 mg dose uses one full single-dose syringe/pen; no drug is discarded in routine adult use. JW applies only when documented wastage occurs — which is rare except for weight-based pediatric dosing.

Modifier 25 — situational

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection.

340B modifiers (JG, TB)

For 340B-acquired adalimumab, follow your MAC's current 340B modifier policy — rarely encountered for adalimumab given the pharmacy-benefit dominance.

ICD-10-CM diagnosis codes FY2026 verified May 2026

Adalimumab covers the broadest indication set of any biologic — map carefully.

Site of care & place of service Verified May 2026

Adalimumab is overwhelmingly self-administered at home. Office and hospital outpatient administration occur but are uncommon. Site-of-care UM programs are not typically applied to adalimumab because the default site is already the patient's home.

Claim form field mapping Verified May 2026

CMS-1500 / 837P (physician office, POS 11) — for the rare in-office administration only.

Form references: NUCC (CMS-1500).

Payer / PBM policy snapshot Reviewed May 2026 — Drug Channels 2026

In 2026, the major national PBMs have largely removed Humira reference from preferred status.

What to document for approval (medical or pharmacy benefit)

• Confirmed FDA-approved indication with matching ICD-10
• TB screening (PPD or IGRA) within 12 months prior to initiation
• Hepatitis B screening
• For RA/PsA: documented inadequate response to methotrexate (or contraindication)
• For Crohn's / UC: documented step therapy through conventional agents and (for second-line scenarios) prior TNF-inhibitor history
• For HS: confirmation of weekly maintenance dosing
• Confirmation of preferred biosimilar product where Humira reference is non-preferred

Medicare reimbursement CMS Q2 2026 — pharmacy benefit primary

Adalimumab is overwhelmingly Part D (pharmacy) for Medicare beneficiaries. Part B reimbursement applies only when administered in office.

Coverage

No NCD specific to adalimumab. Medicare Part B coverage for in-office administration falls under generic drug-coverage LCDs (e.g., LCD L33394). Medicare Part D coverage is plan-specific; nearly all Part D plans cover at least one preferred adalimumab product (typically a biosimilar in 2026).

Code history

• 2002 — FDA approval of Humira reference (BLA 125057)
• J0135 — "Injection, adalimumab, 20 mg" (1 unit = 20 mg) — legacy reference code, still active
• J0139 — "Injection, adalimumab, 1 mg" (1 unit = 1 mg) — alternate per-mg basis used by Aetna policy and several MACs
• Q5140–Q5145 — permanent biosimilar Q-codes (Hulio, Yuflyma, Simlandi, Cyltezo, Idacio, Abrilada)
• Amjevita, Hadlima, Hyrimoz, Yusimry — bill J3490 / J3590 / C9399 until product-specific Q-codes issue

Patient assistance — Humira Complete + biosimilar programs Manufacturer verified May 2026

Humira reference (AbbVie)

• Humira Complete: AbbVie copay savings card — eligible commercially-insured patients pay as little as $5/month. Excludes Medicare, Medicaid, federal program patients.
• Phone: 1-800-4HUMIRA (1-800-448-6472)
• Web: humira.com/humira-complete
• Nurse Ambassador program: in-home injection training and ongoing support

Biosimilar copay programs

• Cyltezo Connect (Boehringer Ingelheim) — copay assistance for commercially-insured patients
• Simlandi Plus (Alvotech / Teva) — copay support program
• Celltrion CARES — for Yuflyma; copay and access support
• Pfizer enCompass — for Abrilada; commercial copay assistance
• Sandoz One Source — for Hyrimoz; copay and PA support
• Idacio Direct (Fresenius Kabi)
• Yusimry connection (Coherus BioSciences)

Foundations (income-eligible, including Medicare)

• HealthWell Foundation — disease-fund-based assistance for adalimumab indications
• PAN Foundation — disease-fund grants
• Good Days — specialty drug assistance for chronic conditions

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Humira?

Humira (adalimumab) reference product is billed under HCPCS J0135 — "Injection, adalimumab, 20 mg" (1 unit = 20 mg) or J0139 — "Injection, adalimumab, 1 mg" (1 unit = 1 mg). Both codes are in active use depending on Medicare Administrative Contractor (MAC) and payer. A standard 40 mg dose bills as 2 units of J0135 OR 40 units of J0139. These codes apply only when adalimumab is administered in a physician office under the medical benefit — which is rare. >95% of Humira utilization runs through the pharmacy benefit (self-injected at home, dispensed by specialty pharmacy).

Is Humira a pharmacy benefit or medical benefit drug?

Pharmacy benefit, overwhelmingly. Humira and its biosimilars are subcutaneous injections designed for patient self-administration at home (prefilled syringe or autoinjector pen). They are dispensed through specialty pharmacy and adjudicated under the pharmacy benefit. The J-codes (J0135, J0139) and the biosimilar Q-codes (Q5140–Q5145) only apply when adalimumab is administered in a physician office under the medical benefit — an uncommon scenario. For the vast majority of patients, no medical-benefit claim is generated for Humira.

What are the biosimilar Q-codes for Humira?

Six adalimumab biosimilars have permanent Q-codes: Q5140 (Hulio, adalimumab-fkjp, Biocon), Q5141 (Yuflyma, adalimumab-aaty, Celltrion — interchangeable), Q5142 (Simlandi, adalimumab-ryvk, Alvotech/Teva — interchangeable, citrate-free high-concentration), Q5143 (Cyltezo, adalimumab-adbm, Boehringer Ingelheim — first interchangeable adalimumab biosimilar), Q5144 (Idacio, adalimumab-aacf, Fresenius Kabi), and Q5145 (Abrilada, adalimumab-afzb, Pfizer — interchangeable). Four additional biosimilars (Amjevita, Hadlima, Hyrimoz, Yusimry) currently bill under unclassified codes J3490 / J3590 / C9399 when administered medically.

Which adalimumab biosimilars are FDA-designated interchangeable?

Four: Cyltezo (Q5143, Boehringer Ingelheim — first FDA-designated interchangeable adalimumab biosimilar), Abrilada (Q5145, Pfizer — October 2023), Yuflyma (Q5141, Celltrion — April 2024), and Simlandi (Q5142, Alvotech/Teva). Interchangeability allows pharmacy-level substitution where state law permits, without prescriber intervention.

What is the difference between citrate-free and citrate-containing adalimumab?

Citrate-free / high-concentration formulations (100 mg/mL) deliver a 40 mg dose in a smaller volume (0.4 mL) and are reported by patients to cause less injection-site pain. Citrate-containing formulations (50 mg/mL, 0.8 mL) have historically been associated with more injection burning. Modern Humira is citrate-free. Citrate-free biosimilars include Simlandi, Yuflyma, Cyltezo HC, Hyrimoz HC, Abrilada HC, and Hadlima HC. Citrate-containing options include the original Amjevita, original Hyrimoz LC, Yusimry, Idacio, and Hulio (varies by SKU). Many 2026 payer formularies prefer citrate-free formulations.

Are PBMs excluding branded Humira in 2026?

Yes — at most national PBMs, branded Humira is non-preferred or excluded in 2026. CVS Caremark prefers Sandoz biosimilars (Hyrimoz/Cordavis private-label) and Biocon Hulio. Express Scripts prefers Cyltezo (Boehringer Ingelheim), Simlandi (Alvotech/Teva), and Hyrimoz (Sandoz). OptumRx specifically excluded Cyltezo from 2026 formularies. Per Drug Channels, the major PBMs have largely removed Humira reference and Stelara reference from their preferred lists. Approximately 98.5% of biologic plans require step therapy through cheaper agents before approving branded Humira.

What are the boxed warnings for Humira?

Two boxed warnings apply to Humira and all adalimumab biosimilars: (1) SERIOUS INFECTIONS — including tuberculosis (latent and active), invasive fungal infections (histoplasmosis, coccidioidomycosis, candidiasis), and other opportunistic infections. TB screening required before initiation. (2) MALIGNANCY — including lymphoma and other malignancies, particularly hepatosplenic T-cell lymphoma (HSTCL) in adolescents and young adults treated for inflammatory bowel disease, often in combination with azathioprine or 6-mercaptopurine.

What is the administration code for Humira when given in office?

CPT 96372 — "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular." Adalimumab is non-chemotherapeutic, so 96401 (chemotherapy SC/IM admin) is NOT appropriate. When the patient self-administers at home, NO administration CPT is billed — only the pharmacy claim is generated.

How is Humira dosed by indication?

Adult RA, PsA, and AS: 40 mg SC every other week. Crohn's disease (adult): 160 mg loading on Day 1 (or 80 mg on each of two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29. Ulcerative colitis (adult): 160 mg loading, 80 mg on Day 15, then 40 mg every other week. Plaque psoriasis (adult): 80 mg loading, then 40 mg every other week starting one week after the loading dose. Hidradenitis suppurativa: 160 mg Day 1, 80 mg Day 15, then 40 mg WEEKLY (not every other week). Pediatric polyarticular JIA: weight-based — 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (≥30 kg) every other week.

What is the patient assistance program for Humira?

Humira Complete is AbbVie's copay savings program — eligible commercially-insured patients pay as little as $5 per month. Excludes Medicare, Medicaid, and other federal program patients. Contact 1-800-4HUMIRA (1-800-448-6472). Each biosimilar has its own copay assistance program: Cyltezo Connect (Boehringer Ingelheim), Simlandi Plus (Alvotech/Teva), Celltrion CARES for Yuflyma, Pfizer enCompass for Abrilada, Sandoz One Source for Hyrimoz, Idacio Direct (Fresenius Kabi), and Yusimry connection (Coherus). Income-eligible Medicare patients should be referred to independent foundations: HealthWell Foundation, PAN Foundation, and Good Days.

Source documents

1. DailyMed — HUMIRA (adalimumab) Prescribing Information
   FDA-approved label (BLA 125057)
2. HCPCSdata — J0135 ("Injection, adalimumab, 20 mg")
   Confirms 20 mg/unit basis — common reference error attributes 1 mg/unit to J0135
3. HCPCSdata — J0139 ("Injection, adalimumab, 1 mg")
   Alternate per-mg basis used by Aetna policy and several MACs
4. AAPC — HCPCS Q5140 (Hulio, adalimumab-fkjp)
5. AAPC — HCPCS Q5141 (Yuflyma, adalimumab-aaty)
6. AAPC — HCPCS Q5142 (Simlandi, adalimumab-ryvk)
7. AAPC — HCPCS Q5143 (Cyltezo, adalimumab-adbm)
8. AAPC — HCPCS Q5144 (Idacio, adalimumab-aacf)
9. AAPC — HCPCS Q5145 (Abrilada, adalimumab-afzb)
10. Aetna Clinical Policy Bulletin 0655 — Adalimumab
    PA criteria, step therapy, J0139 (1 mg) coding basis
11. AbbVie — Humira Pro coding & reimbursement guide
    Manufacturer coding guidance, NDC reference, copay program detail
12. FDA — Biosimilar Product Information / Purple Book
    Adalimumab biosimilars approval status, interchangeability designations
13. Drug Channels Institute — 2026 PBM formulary exclusions analysis
    CVS Caremark, Express Scripts, OptumRx 2026 Humira / biosimilar positioning
14. CMS — Medicare Part B Drug ASP Pricing File
    Q2 2026 quarterly file (medical-benefit reimbursement only; pharmacy benefit primary for adalimumab)
15. CMS — HCPCS quarterly update file (canonical J-code / Q-code source)
16. FDA National Drug Code Directory
17. FDA Drugs@FDA — HUMIRA (BLA 125057) approval history
    Initial FDA approval December 31, 2002

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files — though for adalimumab, Part B ASP applies only to the rare in-office administration scenario. Coding, payer policy, and biosimilar formulary content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. Pharmacy-benefit-primary framing throughout. Six Q-coded biosimilars catalogued (Q5140–Q5145) with interchangeability and citrate-free status. 2026 PBM formulary exclusions documented (CVS / ESI / OptumRx). Aetna CPB 0655 cited for J0139 (1 mg) coding basis. HCPCSdata cited for J0135 = 20 mg/unit (correcting common reference error).

Methodology

Every claim on this page is sourced inline. PBM formulary positioning is read from each PBM's published 2026 formulary documents and triangulated against Drug Channels Institute's 2026 exclusions analysis. HCPCS unit basis is verified against HCPCSdata (J0135 = 20 mg, J0139 = 1 mg) because many billing-software vendor references incorrectly attribute 1 mg/unit to J0135. Biosimilar interchangeability status is read from the FDA Purple Book. We do not paraphrase from billing-software vendor blogs. When MAC interpretation is ambiguous (J0135 vs. J0139 preference), we surface the ambiguity rather than asserting a definitive answer.